Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Fransson

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Palliative Medicine|April 30, 2026
Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL)Kathrin Wode, Ove Björ, Reinhild Klein, et al.
Cost Effectiveness and Resource Allocation : C/E|September 13, 2024
Cost-effectiveness of proton beam therapy vs. conventional radiotherapy for patients with brain tumors in Sweden: results from a non-randomized prospective multicenter studyFilipa Sampaio, Ulrica Langegård, Patricio Martínez de Alva, et al.
Lancet (London, England)|December 19, 2008
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trialAnders Widmark, Olbjørn Klepp, Arne Solberg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 20, 2024
Patient reported fatigue after proton therapy for malignant brain tumours - Is there a relation between radiation dose and brain structures?Ingrid Kristensen, Ulrica Langegård, Thomas Björk-Eriksson, et al.
Advances in Radiation Oncology|July 7, 2025
Association of Circulating Inflammatory Biomarker Levels and Toxicity in Patients Undergoing Pelvic Radiation for Cancer: A Critical ReviewPer Fessé, Per-Arne Svensson, Björn Zackrisson, et al.
International Journal of Epidemiology|May 8, 2012
Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0Mieke Van Hemelrijck, Annette Wigertz, Fredrik Sandin, et al.
Deutsches Arzteblatt International|June 25, 2024
Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a Double-Blind, Randomized, Placebo-Controlled Tial (MISTRAL)Kathrin Wode, Gunver S Kienle, Ove Björ, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 1, 2017
Prognosis is similar for patients who undergo primary PCI during regular-hours and off-hours: A report from SCAARBjörn Redfors, Christian Dworeck, Oskar Angerås, et al.
The Lancet. Oncology|February 8, 2026
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trialPer Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology|January 14, 2021
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trialPer Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Palliative Medicine|April 30, 2026
Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL)Kathrin Wode, Ove Björ, Reinhild Klein, et al.
Cost Effectiveness and Resource Allocation : C/E|September 13, 2024
Cost-effectiveness of proton beam therapy vs. conventional radiotherapy for patients with brain tumors in Sweden: results from a non-randomized prospective multicenter studyFilipa Sampaio, Ulrica Langegård, Patricio Martínez de Alva, et al.
Lancet (London, England)|December 19, 2008
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trialAnders Widmark, Olbjørn Klepp, Arne Solberg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 20, 2024
Patient reported fatigue after proton therapy for malignant brain tumours - Is there a relation between radiation dose and brain structures?Ingrid Kristensen, Ulrica Langegård, Thomas Björk-Eriksson, et al.
Advances in Radiation Oncology|July 7, 2025
Association of Circulating Inflammatory Biomarker Levels and Toxicity in Patients Undergoing Pelvic Radiation for Cancer: A Critical ReviewPer Fessé, Per-Arne Svensson, Björn Zackrisson, et al.
International Journal of Epidemiology|May 8, 2012
Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0Mieke Van Hemelrijck, Annette Wigertz, Fredrik Sandin, et al.
Deutsches Arzteblatt International|June 25, 2024
Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a Double-Blind, Randomized, Placebo-Controlled Tial (MISTRAL)Kathrin Wode, Gunver S Kienle, Ove Björ, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 1, 2017
Prognosis is similar for patients who undergo primary PCI during regular-hours and off-hours: A report from SCAARBjörn Redfors, Christian Dworeck, Oskar Angerås, et al.
The Lancet. Oncology|February 8, 2026
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trialPer Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology|January 14, 2021
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trialPer Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, et al.
Pageof 10